Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A study to assess the efficacy and feasibility of adding pioglitazone to imatinib in patients of CML with suboptimal response in a resource-limited setting

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Shina Goyal

Citation

Annals of Oncology (2020) 31 (suppl_1): S13-S15. 10.1016/annonc/annonc83

Authors

S. Goyal1, G. Babu2, D. Lokanatha2, J.A. Linu2, K..N. Lokesh2, A.H. Rudresha2, L.K. Rajeev2, S. Smitha2

Author affiliations

  • 1 Medical Oncology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
  • 2 Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
More

Resources

Chronic myeloid leukemia (CML) is characterized by the production of BCR-ABL oncoprotein that has enhanced tyrosine kinase activity. The use of imatinib has redefined the survival of CML patients. Further understanding of disease pathogenesis has led to the identification of quiescent CML Leukemic Stem Cells (LSC) that are resistant to tyrosine kinase inhibitors (TKI) and lead to failure to achieve complete molecular response in many patients. The PPAR-γ agonists can purge them out of quiescence, thereby sensitizing them to imatinib. Hence, combining the two can act in synergy to deplete the leukemic cells. The objective of our study was to determine if the addition of PPAR-γ agonist, pioglitazone to imatinib could attain major molecular response (MMR) in patients who fail to achieve optimal response with imatinib.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings